Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL819638 | 0.84 | ALDH1A1 (0.33) | MEN1ALDH1A1HTTKMT2APOLB | |
| Hydrochloric Acid SCHEMBL818981 | 0.82 | ALDH1A1 (0.32) | MEN1ALDH1A1HTTKMT2APOLB | |
| SCHEMBL1947927 | 0.81 | MEN1 (0.31) | MEN1ALDH1A1LMNATSHRHTT | |
| Hydrochloric Acid SCHEMBL1609624 | 0.79 | — | — | |
| SCHEMBL29602996 | 0.74 | ALDH1A1 (0.34) | MEN1ALDH1A1HTTKMT2AMAPT | |
| SCHEMBL28731966 | 0.73 | ALDH1A1 (0.33) | MEN1ALDH1A1HTTKMT2AMAPT | |
| SCHEMBL29603731 | 0.73 | ALDH1A1 (0.33) | MEN1ALDH1A1HTTKMT2AMAPT | |
| SCHEMBL18966845 | 0.70 | HTR7 (0.33) | ACHEHTR7PDE7A | |
| Hydrochloric Acid SCHEMBL23326869 | 0.67 | GABRA1 (0.36) | ALDH1A1LMNATSHR | |
| Hydrochloric Acid SCHEMBL23326872 | 0.67 | ANPEP (0.36) | MEN1ALDH1A1LMNATSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210053043-A1 | OLEFIN METATHESIS CATALYSTS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2021-02-25 | — | — | US | disclosed |
| US-10857530-B2 | Olefin metathesis catalysts | UMICORE AG & CO. KG (DE) | 2020-12-08 | — | — | US | disclosed |
| WO-2017100585-A1 | OLEFIN METATHESIS CATALYSTS | MATERIA, INC. (US) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10857530-B2 | Olefin metathesis catalysts | ZDHHC7, ZDHHC2, OSBP | ACHE 1252/4885HTR7 2875/4885MEN1 524/4885 |
| US-20210053043-A1 | OLEFIN METATHESIS CATALYSTS | ZDHHC7, ZDHHC2, OSBP | ACHE 1252/4885HTR7 2875/4885MEN1 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.